Our Pricing

Comparing 8 Week Mounjaro Results With Other Options

Published on: June 03, 2026

Understanding 8 week mounjaro results uk outcomes helps set realistic expectations when starting weight loss treatment. At Cured Pharmacy, our UK-registered clinical team provides transparent guidance on what tirzepatide and alternative treatments may achieve in your first two months, supported by clinical trial data and patient experience.

What to Expect From 8 Week Mounjaro Results UK

Mounjaro (tirzepatide) works as a dual GIP/GLP-1 receptor agonist, producing measurable weight loss within the first 8 weeks of treatment [1]. In the SURMOUNT-1 trial, participants on the 5mg maintenance dose achieved an average 5.4% body weight reduction by week 8, with many patients reporting reduced appetite and improved satiety control during this initial phase [1].

Individual results vary based on starting weight, adherence to the dosing schedule, and lifestyle factors including diet and physical activity. During the first 8 weeks, patients typically progress from the 2.5mg initiation dose to 5mg, allowing the body to adjust gradually whilst minimising gastrointestinal side effects [1]. Your UK prescriber will monitor progress and adjust dosing according to your response and tolerability.

It's important to note that 8 weeks represents the early phase of treatment. Clinical trials demonstrate that weight loss continues progressively over 72 weeks, with the most significant reductions occurring between weeks 20 and 52 [1]. Setting realistic short-term expectations helps maintain motivation throughout your weight management programme.

Mounjaro vs Wegovy: 8 Week Results Comparison

Both Mounjaro and Wegovy are once-weekly injectable treatments licensed by the MHRA for weight management, but they operate through different mechanisms. Wegovy contains semaglutide, a single GLP-1 receptor agonist, whilst Mounjaro's tirzepatide activates both GIP and GLP-1 pathways [1][2].

In head-to-head comparison, the SURPASS-2 trial showed tirzepatide produced superior weight loss compared to semaglutide at comparable timepoints [3]. By week 8, patients on tirzepatide 5mg demonstrated approximately 1.5-2% greater body weight reduction than those on semaglutide 1mg, though both treatments showed clinically meaningful results during this early phase [3].

Wegovy follows a different dose escalation schedule, starting at 0.25mg and increasing monthly to the 2.4mg maintenance dose over 16-20 weeks. This means patients on Wegovy may experience more gradual initial weight loss compared to Mounjaro's faster titration schedule. Your UK prescriber will recommend the most appropriate option based on your medical history, previous treatment responses, and individual circumstances.

Side Effect Profiles in the First 8 Weeks

Both medications commonly cause gastrointestinal side effects during the initial weeks, including nausea, diarrhoea, and reduced appetite [1][2]. These effects typically peak during dose escalation and diminish as the body adjusts. In clinical trials, approximately 20-30% of tirzepatide users reported mild to moderate nausea during the first month, with most cases resolving by week 8 [1]. Starting with the lowest dose and following the prescribed titration schedule helps minimise these temporary effects whilst your system adapts to treatment.

Comparing Mounjaro With Saxenda and Orlistat After 8 Weeks

Saxenda (liraglutide) requires daily injections rather than weekly administration, delivering a different GLP-1 agonist that has been available in the UK since 2015. In the SCALE trial, Saxenda users achieved an average 2.8% body weight reduction by week 8 when combined with reduced-calorie diet and increased physical activity [4].

Orlistat works through a completely different mechanism as a lipase inhibitor, blocking approximately 30% of dietary fat absorption in the digestive system. Clinical data shows Orlistat users typically achieve 1-2% weight loss in the first 8 weeks when adhering to a low-fat diet, with results dependent on dietary fat intake and compliance [5]. Unlike GLP-1 treatments, Orlistat does not affect appetite hormones or blood sugar regulation.

The choice between injectable GLP-1 treatments and oral medications like Orlistat depends on individual preferences, medical history, and treatment goals. Injectable options generally produce greater weight loss in clinical trials but require comfort with self-administration, whilst Orlistat offers a non-injectable alternative for patients who prefer oral medication. All prescription weight loss treatments available through Cured Pharmacy require clinical assessment by a UK prescriber to ensure suitability and safety.

Administration and Lifestyle Considerations

Mounjaro and Wegovy require once-weekly subcutaneous injection using a pre-filled pen device, typically administered in the abdomen, thigh, or upper arm. Saxenda requires daily injection at the same time each day. Most patients find the injection process straightforward after initial guidance, with minimal discomfort reported in clinical trials. Orlistat is taken orally three times daily with main meals containing fat, requiring consistent adherence to the dosing schedule and dietary modifications to achieve optimal results and minimise gastrointestinal side effects.

Factors That Influence Your 8 Week Mounjaro Results

Starting body weight significantly impacts percentage weight loss in clinical trials. Patients with higher baseline BMI often demonstrate greater absolute weight reduction, though percentage changes remain consistent across weight categories [1]. Your UK prescriber will establish realistic targets based on your individual starting point and health objectives.

Adherence to the prescribed dosing schedule directly affects outcomes. Missing doses or inconsistent administration can reduce treatment effectiveness and may increase side effects when restarting. The once-weekly administration of Mounjaro offers practical advantages for busy schedules compared to daily injectable alternatives.

Dietary habits and physical activity levels complement medication effects. Whilst Mounjaro reduces appetite and improves satiety through hormonal pathways, combining treatment with a balanced, reduced-calorie diet and regular movement enhances results. Clinical trials included lifestyle intervention alongside medication, demonstrating the importance of comprehensive weight management approaches [1]. Your prescriber may recommend nutritional guidance or refer you to additional support services available through the NHS or private providers.

Managing Expectations: Beyond the First 8 Weeks

Weight loss with Mounjaro follows a progressive trajectory, with the most substantial reductions occurring between months 3 and 12 of treatment. The SURMOUNT-1 trial demonstrated that participants on the 15mg maintenance dose achieved an average 22.5% body weight reduction over 72 weeks, with approximately one-third of this loss occurring after week 20 [1].

Dose escalation continues beyond the initial 8 weeks for most patients. After starting at 2.5mg and increasing to 5mg, your prescriber may recommend further increases to 7.5mg, 10mg, 12.5mg, or 15mg based on your response and tolerability. Each dose increase occurs at 4-week intervals, allowing time to assess effectiveness and side effects at each level [1].

Long-term success requires ongoing commitment to treatment and lifestyle modifications. Clinical trials show that discontinuing medication typically results in weight regain, highlighting the importance of viewing these treatments as long-term management tools rather than short-term solutions. Regular follow-up with your UK prescriber ensures appropriate dose adjustments and monitoring for potential complications throughout your treatment journey.

When to Contact Your Prescriber

Seek medical advice if you experience severe or persistent side effects including severe abdominal pain, signs of pancreatitis, allergic reactions, or significant dehydration from vomiting or diarrhoea. Your prescriber should also be contacted if you notice no weight loss after 12 weeks at the maintenance dose, as alternative treatments may be more appropriate. Regular monitoring ensures safe, effective treatment tailored to your individual response and changing health needs.

Accessing Mounjaro Through Cured Pharmacy

Cured Pharmacy offers genuine UK-licensed Mounjaro KwikPens from £124.99, with transparent upfront pricing shown before your free online consultation. As a registered UK pharmacy (GPhC 9012511) under superintendent pharmacist Tarun Kumar (GPhC 2233073), we dispense only MHRA-approved medications following clinical assessment by UK-registered prescribers.

The online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and suitability for treatment. Our clinical team reviews your assessment and, if appropriate, issues a prescription for collection or discreet home delivery. All prescription weight loss treatments require this clinical approval to ensure patient safety and appropriate use.

We guarantee the lowest prices in the UK for genuine licensed medications, with 100% discreet packaging and no hidden fees. If you're currently using weight loss treatment or considering alternatives, our team can provide guidance on switching between medications or adjusting your current regimen. Start your free assessment today to discuss whether Mounjaro or an alternative treatment suits your individual circumstances and health objectives.

Scientific References

1. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Torgerson, J. S., et al. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and are not guaranteed. Weight loss outcomes depend on multiple factors including adherence to treatment, diet, exercise, and individual metabolism.